mTORC1 vs mTORC2: Two Complexes, Different Jobs

Different Subunits Define Each Complex

Both complexes contain the mTOR kinase, mLST8 and other shared subunits, but the defining partner differs: mTORC1 contains RAPTOR, while mTORC2 contains RICTOR and mSIN1. These scaffolds determine which substrates each complex can reach.

RICTOR is amplified in a minority of tumours and is studied as a way to raise mTORC2 activity, whereas most pathway alterations act upstream and feed mainly into mTORC1.

What Activates mTORC1

mTORC1 sits at a junction of signals. Growth-factor input arrives through PI3K-AKT, which switches off the TSC1-TSC2 complex so that the small GTPase RHEB can activate mTORC1. Amino-acid availability is sensed separately through the Rag GTPases at the lysosome.

Only when both growth-factor and nutrient signals are present is mTORC1 fully on. It then promotes protein synthesis (through S6K1 and 4E-BP1), lipid synthesis and nucleotide production, and it suppresses autophagy.

What mTORC2 Does

mTORC2 is activated more directly by association with ribosomes and PI3K products. Its best-known job is to phosphorylate AKT on serine 473, which is required for full AKT activity, alongside the PDK1 site.

mTORC2 also regulates SGK1 and PKC family kinases, influencing cell survival, metabolism and the actin cytoskeleton. Because mTORC2 lies downstream of PI3K but upstream of AKT, it sits inside a feedback web rather than at a simple end point.

Why Rapamycin Is Not the Whole Story

Rapamycin and its analogues (everolimus, temsirolimus) bind FKBP12 and inhibit mTORC1 substrates only partially, and they do not acutely block mTORC2. Everolimus is approved in hormone-receptor-positive breast cancer, advanced renal cancer, neuroendocrine tumours and TSC-associated lesions.

Incomplete mTORC1 inhibition and relief of a negative feedback loop can paradoxically raise upstream PI3K-AKT signalling, one reason ATP-competitive mTOR kinase inhibitors, which hit both complexes, were developed.

Interpretation Notes

A report may flag alterations in MTOR itself, in TSC1/TSC2, or in RICTOR. These act at different points and are not equivalent, and activating MTOR mutations are uncommon relative to upstream lesions.

mTOR-pathway activity is not routinely measured as a predictive biomarker, and pathway alterations describe a dependency, not a treatment instruction.

Key Takeaways

• ·mTORC1 (RAPTOR) drives anabolic growth from nutrient and growth-factor signals.
• ·mTORC2 (RICTOR) completes AKT activation and shapes survival signalling.
• ·Rapamycin analogues mainly inhibit mTORC1 and can trigger upstream feedback.
• ·MTOR, TSC1/2 and RICTOR alterations are not interchangeable.